Precision Oncology & Cancer Genomics
Session Overview
The integration of genomics into oncology has fundamentally shifted the paradigm of cancer care from organ-based classification to molecularly guided management. This session delves into the core principles and evolving practices of precision oncology, where genomic data directly informs diagnosis, prognostication, and therapeutic strategy. We will explore the complete lifecycle of a cancer genome in the clinic—from initial molecular profiling and biomarker interpretation to the selection of targeted and immunotherapies, the management of resistance, and the multidisciplinary frameworks required for effective implementation.
Why This Session Matters Now
Precision oncology is no longer a theoretical concept but a standard of care for many malignancies, continuously expanding as new biomarkers and targeted agents are validated. This rapid evolution presents ongoing challenges in keeping diagnostic practices current, interpreting complex genomic reports, and navigating an increasingly sophisticated therapeutic landscape. This session addresses the critical need for a cohesive understanding of how genomic insights are systematically translated into personalized treatment plans, ensuring that innovation in cancer genomics directly and effectively benefits patient outcomes.
Key Scientific and Clinical Themes
Tumor genomic profiling and molecular classification
Examining comprehensive approaches to genomic characterization of tumors, including the use of next-generation sequencing panels, whole exome/genome sequencing, and transcriptomics to establish molecular diagnoses and identify actionable alterations.
Targeted therapies and biomarker-driven treatment selection
Focusing on the evidence and guidelines that link specific genomic biomarkers to approved and investigational targeted agents, including kinase inhibitors, PARP inhibitors, and other mechanism-based therapies.
Liquid biopsy for treatment monitoring and early detection
Discussing the application of circulating tumor DNA (ctDNA) analysis to non-invasively monitor treatment response, detect minimal residual disease, identify emergent resistance mechanisms, and explore potential in early cancer detection.
Cancer immunogenomics and neoantigen-based therapies
Exploring how genomic analysis of tumors informs immunotherapy, including the prediction of neoantigens for vaccine development, assessment of tumor mutational burden, and understanding of the genomic correlates of immune checkpoint inhibitor response.
Resistance mechanisms and adaptive treatment strategies
Investigating the genomic evolution of tumors under therapeutic pressure, the molecular basis of acquired resistance, and the strategies for sequential or combination therapies to overcome or prevent resistance.
Clinical implementation through molecular tumor boards
Highlighting the essential role of multidisciplinary molecular tumor boards in synthesizing complex genomic, pathological, and clinical data to formulate evidence-based, patient-specific management recommendations.
Nature of Research in This Field
Research in precision oncology is intensely translational and collaborative, bridging basic cancer biology, clinical trial design, and real-world evidence generation. It encompasses biomarker discovery and validation, companion diagnostic development, clinical outcomes research, and health services research focused on implementation. This work requires close integration between oncologists, pathologists, genomic scientists, bioinformaticians, and clinical trialists. The field is characterized by a rapid feedback loop where clinical observations drive mechanistic research, which in turn informs the next generation of clinical trials and treatment guidelines.
Who Should Attend
This session is designed for:
- Medical, surgical, and radiation oncologists.
- Molecular pathologists and cytopathologists.
- Clinical cancer geneticists and genetic counselors.
- Clinical bioinformaticians and scientists in cancer genomics.
- Researchers in cancer biology and translational therapeutics.
- Clinical trial coordinators and professionals from the pharmaceutical industry.
- Fellows and trainees in oncology, pathology, and clinical genomics.
Session Perspective
“Precision Oncology & Cancer Genomics” represents the forefront of a personalized approach to cancer medicine. This session underscores that effective precision oncology relies on more than a genomic test result; it requires the seamless integration of accurate data, expert interpretation, and agile clinical decision-making within a multidisciplinary framework. By examining the entire pathway from tumor sequencing to tailored treatment, this session highlights the critical components and standards of practice that ensure patient care is guided by an insightful reading of the cancer’s unique genomic blueprint.
If your research aligns with this session, we invite you to submit an abstract for consideration.
